Quick Answer
BICYCLE THERAPEUTICS PLC reported Total Revenue of $72.59 million for fiscal year 2025.
BICYCLE THERAPEUTICS PLC — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $72.59M +105.8% |
$35.27M +30.8% |
$26.98M +86.5% |
$14.46M +23.6% |
$11.70M +12.6% |
$10.39M -24.7% |
| Revenue (ASC 606) | $72.59M +105.8% |
$35.27M +30.8% |
$26.98M +86.5% |
$14.46M +23.6% |
$11.70M +12.6% |
$10.39M -24.7% |
| Net Income | -$218.96M -29.5% |
-$169.03M +6.4% |
-$180.66M -60.3% |
-$112.72M -68.7% |
-$66.82M -31.0% |
-$51.01M -66.7% |
| Diluted EPS | -$3.16 -9.0% |
-$2.90 +42.9% |
-$5.08 -33.7% |
-$3.80 -42.3% |
-$2.67 -0.4% |
-$2.66 +4.0% |
| Total Assets | $717.60M -25.0% |
$956.87M +60.7% |
$595.34M +45.0% |
$410.61M -14.4% |
$479.79M +197.7% |
$161.15M +46.2% |
| Cash and Equivalents | $628.11M -28.6% |
$879.52M +67.1% |
$526.42M +55.2% |
$339.15M -22.7% |
$438.68M | — |
| Long-Term Debt | — | — | $30.70M +1.3% |
$30.32M +1.5% |
$29.87M +105.9% |
$14.51M |
| Stockholders Equity | $609.98M -23.1% |
$793.06M +113.8% |
$370.93M +37.0% |
$270.78M -21.8% |
$346.25M +262.7% |
$95.46M +2.4% |
| R&D Expense | $240.28M +38.9% |
$172.97M +10.5% |
$156.50M +91.8% |
$81.61M +81.8% |
$44.88M +35.4% |
$33.15M +29.8% |
| Operating Income | -$247.06M -17.7% |
-$209.87M -10.5% |
-$189.95M -62.8% |
-$116.65M -77.8% |
-$65.62M -26.3% |
-$51.96M -97.6% |
| Shares Outstanding | 69.37M +0.4% |
69.06M +62.8% |
42.43M +42.0% |
29.87M +1.0% |
29.58M +40.2% |
21.09M +17.2% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $11.73M | +338.5% | +301.8% |
| Revenue (ASC 606) | September 30, 2025 | $11.73M | +338.5% | +301.8% |
| Net Income | September 30, 2025 | -$59.10M | -16.3% | +25.1% |
| Diluted EPS | September 30, 2025 | -$0.85 | -14.9% | +25.4% |
| Total Assets | September 30, 2025 | $763.95M | -23.4% | -8.2% |
| Cash and Equivalents | September 30, 2025 | $648.33M | -27.2% | -10.1% |
| Long-Term Debt | June 30, 2024 | $8.51M | -72.1% | -72.4% |
| Stockholders Equity | September 30, 2025 | $618.48M | -25.6% | -7.5% |
| R&D Expense | September 30, 2025 | $58.43M | +21.1% | -17.7% |
| Operating Income | September 30, 2025 | -$65.55M | -2.7% | +24.3% |
| Shares Outstanding | September 30, 2025 | 69.31M | +0.4% | +0.1% |
- BICYCLE THERAPEUTICS PLC reported Total Revenue of $72.59 million for fiscal year 2025.
- BICYCLE THERAPEUTICS PLC showed an increase of +105.8% in Total Revenue compared to the prior fiscal year.
- BICYCLE THERAPEUTICS PLC reported Revenue (ASC 606) of $72.59 million for fiscal year 2025.
- BICYCLE THERAPEUTICS PLC showed an increase of +105.8% in Revenue (ASC 606) compared to the prior fiscal year.
- BICYCLE THERAPEUTICS PLC reported Net Income of -$218.96 million for fiscal year 2025.
- BICYCLE THERAPEUTICS PLC showed a decrease of -29.5% in Net Income compared to the prior fiscal year.
- BICYCLE THERAPEUTICS PLC reported Diluted EPS of $3.16 per share (loss) for fiscal year 2025.
- BICYCLE THERAPEUTICS PLC showed a decrease of -9.0% in Diluted EPS compared to the prior fiscal year.
- BICYCLE THERAPEUTICS PLC reported Total Assets of $717.60 million for fiscal year 2025.
- BICYCLE THERAPEUTICS PLC showed a decrease of -25.0% in Total Assets compared to the prior fiscal year.
- BICYCLE THERAPEUTICS PLC reported Cash and Equivalents of $628.11 million for fiscal year 2025.
- BICYCLE THERAPEUTICS PLC showed a decrease of -28.6% in Cash and Equivalents compared to the prior fiscal year.
- BICYCLE THERAPEUTICS PLC reported Long-Term Debt of $30.70 million for fiscal year 2023.
- BICYCLE THERAPEUTICS PLC showed an increase of +1.3% in Long-Term Debt compared to the prior fiscal year.
- BICYCLE THERAPEUTICS PLC reported Stockholders Equity of $609.98 million for fiscal year 2025.
- BICYCLE THERAPEUTICS PLC showed a decrease of -23.1% in Stockholders Equity compared to the prior fiscal year.
- BICYCLE THERAPEUTICS PLC reported R&D Expense of $240.28 million for fiscal year 2025.
- BICYCLE THERAPEUTICS PLC showed an increase of +38.9% in R&D Expense compared to the prior fiscal year.
- BICYCLE THERAPEUTICS PLC reported Operating Income of -$247.06 million for fiscal year 2025.
- BICYCLE THERAPEUTICS PLC showed a decrease of -17.7% in Operating Income compared to the prior fiscal year.
- BICYCLE THERAPEUTICS PLC reported Shares Outstanding of 69.37 million shares for fiscal year 2025.
- BICYCLE THERAPEUTICS PLC showed an increase of +0.4% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: